Skye Bioscience (SKYE) director awarded 75,000 stock options at $0.6150

Rhea-AI Filing Summary

Skye Bioscience director Deborah H. Charych received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $0.6150 per share, expires on March 31, 2036, and was awarded at no cost as a compensation grant.

The stock option vests in equal monthly installments over a one-year period beginning March 31, 2026. Following this grant, Charych holds 75,000 stock options directly, giving her the right to buy an equivalent number of common shares if she chooses to exercise in the future.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Charych Deborah H.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	75,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 75,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 75,000 options Exercise price: $0.6150 per share Expiration date: March 31, 2036 +1 more

4 metrics

Option grant size 75,000 options Stock Option (Right to Buy) granted March 31, 2026

Exercise price $0.6150 per share Exercise price for 75,000 stock options

Expiration date March 31, 2036 Option grant expiration

Underlying shares 75,000 shares Common Stock underlying the option grant

Key Terms

Stock Option (Right to Buy), exercise price, vests in equal monthly installments, grant/award acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "0.6150""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in equal monthly installments financial

"The stock option vests in equal monthly installments over the one year period"

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Charych Deborah H.

(Last) (First) (Middle)

11250 EL CAMINO REAL

SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.615	03/31/2026		A		75,000		(1)	03/31/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Remarks:

	/s/ Punit S. Dhillon, as Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Deborah H. Charych receive in this Skye Bioscience (SKYE) Form 4 filing?

Deborah H. Charych received a stock option grant for 75,000 shares of Skye Bioscience Common Stock. The option was granted as compensation at no cost, giving her the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Deborah Charych’s new Skye Bioscience (SKYE) stock options?

The stock options granted to Deborah Charych have an exercise price of $0.6150 per share. This means she can purchase up to 75,000 Skye Bioscience common shares at $0.6150 each if she chooses to exercise the options later.

How and when do Deborah Charych’s Skye Bioscience (SKYE) options vest?

The stock option vests in equal monthly installments over one year, beginning March 31, 2026. This structure means a portion of the 75,000 options becomes exercisable each month during that year, aligning vesting with continued service over time.

When do Deborah Charych’s Skye Bioscience (SKYE) stock options expire?

Deborah Charych’s stock options expire on March 31, 2036. After that date, any unexercised options will lapse, and she will no longer have the right to buy Skye Bioscience common shares at the $0.6150 exercise price under this grant.

How many Skye Bioscience (SKYE) stock options does Deborah Charych hold after this grant?

Following this grant, Deborah Charych holds 75,000 stock options directly. Each option represents the right to purchase one share of Skye Bioscience Common Stock at an exercise price of $0.6150, subject to the monthly vesting schedule through 2027.